Shanghai Puyou Biopharmaceutical

Shanghai Puyou Biopharmaceutical is a clinical-stage biotechnology company specializing in the development of first-in-class therapies for protein conformation diseases. The company utilizes a proprietary platform to target misfolded proteins and toxic aggregates, which are implicated in a variety of conditions including ophthalmological, cardiovascular, and neurodegenerative disorders. Its lead program, CF04, is a recombinant protein eye drop currently in Phase 2 clinical trials for dry eye disease. Puyou Biopharma's approach focuses on neutralizing denatured proteins to prevent the activation of the innate immune system and subsequent inflammation. The company is headquartered in Shanghai's Zhangjiang Science City and maintains a robust pipeline of innovative biologics. It has established strategic partnerships with leading CDMOs to advance its candidates through global clinical development.